|
|
Post by deanbain on Apr 3, 2017 20:39:17 GMT -5
With blurbs of tepid news, I was hoping that the things might get better but at $1.38 (down from over $2 just recently), I don't see any hope. Bankruptcy or delisting is real. The only question is which one will occur first
|
|
|
|
Post by peppy on Apr 3, 2017 20:49:15 GMT -5
Looks bad. Agreed.
Too bad the insulin works so well.
|
|
|
|
Post by nadathing on Apr 3, 2017 20:52:21 GMT -5
Looks bad. Agreed. Too bad the insulin works so well. If it worked that well you would see a significant number of refills. I do not buy that people do not refill due to price. Who would fill a script if they knew they couldn't afford to refill it? The reality is, not many are having success with Afrezza that we thought we'd see. |
|
|
|
Post by slugworth008 on Apr 3, 2017 21:13:48 GMT -5
Looks bad. Agreed. Too bad the insulin works so well. If it worked that well you would see a significant number of refills. I do not buy that people do not refill due to price. Who would fill a script if they knew they couldn't afford to refill it? The reality is, not many are having success with Afrezza that we thought we'd see. I actually believe it "Does" work well but requires some trial and error to fine tune dosage. Pricing should have been aggressively addressed long ago IMO - The continued slide is truly depressing. The market obviously believes significant dilution is coming and with scripts NOT growing the shorts are making a killing. Due to my own stupidity I am way, way down on this one. The only solace I have and it ain't much is that the MANN foundation and the funds holding this are being crushed as well. And to think I almost sold all at 2.17 pre R/S because...wait for it - Scripts were going to increase any week ... Looks like I picked the wrong week to stop sniffing glue. |
|
|
|
Post by sweedee79 on Apr 3, 2017 22:50:31 GMT -5
Looks bad. Agreed. Too bad the insulin works so well. If it worked that well you would see a significant number of refills. I do not buy that people do not refill due to price. Who would fill a script if they knew they couldn't afford to refill it? The reality is, not many are having success with Afrezza that we thought we'd see. I does work ... but if docs aren't that receptive and not prescribing it as they should be it creates failure... For us we had to discontinue use because the docs weren't very cooperative .. wouldn't raise the dose as needed .. and insurance refused to pay .. As some have pointed out here it takes quite a lot more Afrezza in order to get the success we have seen..
I don't care who buys it... its an amazing insulin.. that is a fact and this is so sad ..
|
|
|
|
Post by silentknight on Apr 3, 2017 22:56:46 GMT -5
It does indeed look grim. Daily sell offs of 5%+ will have Mnkd receiving a delisting notice only a month or so after having to R/S to clear up the one before. The saddest part is that MNKD can't do a single thing to stop it. They have lost the ability to support their stock. I see bankruptcy before the end of the year. I'm not voting for another R/S.
I've come to the conclusion that Afrezza won't sell. Period. Sanofi couldn't do it. Mankind can't do it. Doctors don't like it. Patients don't want it. If any of that were untrue, they'd be selling more than 250 per week.
I've thrown a lot of money at this lemon and this will be the most expensive lesson I wager I'll ever have.
|
|
|
|
Post by madog365 on Apr 3, 2017 23:32:47 GMT -5
Shorts are toast!
|
|
|
|
Post by cjm18 on Apr 3, 2017 23:38:03 GMT -5
If it worked that well you would see a significant number of refills. I do not buy that people do not refill due to price. Who would fill a script if they knew they couldn't afford to refill it? The reality is, not many are having success with Afrezza that we thought we'd see. I does work ... but if docs aren't that receptive and not prescribing it as they should be it creates failure... For us we had to discontinue use because the docs weren't very cooperative .. wouldn't raise the dose as needed .. and insurance refused to pay .. As some have pointed out here it takes quite a lot more Afrezza in order to get the success we have seen..
I don't care who buys it... its an amazing insulin.. that is a fact and this is so sad ..
Docs wouldn't raise the dose? |
|
boon
Newbie
Posts: 9 
|
Post by boon on Apr 3, 2017 23:54:32 GMT -5
Pretty sickening indeed.
|
|
|
|
Post by mytakeonit on Apr 4, 2017 1:27:57 GMT -5
All I can say is ... I'm loading up on the drops. Missed today's $1.29 ... but, I'll see what I can get on the next drop. All I see in MNKD's future is great news!
|
|
|
|
Post by sportsrancho on Apr 4, 2017 6:17:57 GMT -5
I think we head lower this month and then turn back up in 3 or 4 weeks. I don't think we get below a dollar.
I'm hearing whispers that a few doc's are starting to prescribe. And people are going to their doctors that aren't even PWD and are finding out about Afrezza in the waiting room.
Might be to little to late, but if I keep hearing good things I'll keep buying at these prices or a little lower. ( Not much, just with a few proifts from other stocks.) GL all...
|
|
|
|
Post by kbrion77 on Apr 4, 2017 6:48:31 GMT -5
It does indeed look grim. Daily sell offs of 5%+ will have Mnkd receiving a delisting notice only a month or so after having to R/S to clear up the one before. The saddest part is that MNKD can't do a single thing to stop it. They have lost the ability to support their stock. I see bankruptcy before the end of the year. I'm not voting for another R/S. I've come to the conclusion that Afrezza won't sell. Period. Sanofi couldn't do it. Mankind can't do it. Doctors don't like it. Patients don't want it. If any of that were untrue, they'd be selling more than 250 per week. I've thrown a lot of money at this lemon and this will be the most expensive lesson I wager I'll ever have. I mean thank god they hired a Global People Officer at $365m a year with up to 900,000 in stock options. Maybe he is in charge of placing employees at their next company throughout the year. |
|
|
|
Post by lookingforlogic on Apr 4, 2017 8:25:12 GMT -5
Sirius radio founded in 1990 went up to $69 a share and then down to $0.05 on 02.11.2009 due to the same stubborn articles written by Spencer Osborn and commented in the cheering fashion by the same kind of admiring idiots like risingsceptisism, trend, najak and on and on.
Sirius in early Febuary announced to go bankrupt on 02.17.2009. On the same day Liberty Media bought 40% of shares for $550,000 and we know the rest.
Tesla today is continueing loosing money from the vary start in 2010 at $17 till today at $297.
"When I hear the word culture I reach for my gun."
Hermann Goring
I would like to paraphrase this quote by replacing culture with the bloody PROFIT.
|
|
|
|
Post by nemzter on Apr 4, 2017 8:44:54 GMT -5
Sirius radio founded in 1990 went up to $69 a share and then down to $0.05 on 02.11.2009 due to the same stubborn articles written by Spencer Osborn and commented in the cheering fashion by the same kind of admiring idiots like risingsceptisism, trend, najak and on and on. Sirius in early Febuary announced to go bankrupt on 02.17.2009. On the same day Liberty Media bought 40% of shares for $550,000 and we know the rest. Tesla today is continueing loosing money from the vary start in 2010 at $17 till today at $297. "When I hear the word culture I reach for my gun." Hermann Goring I would like to paraphrase this quote by replacing culture with the bloody PROFIT. You're comparing Matt Pfeffer to Mel Karmazin and Elon Musk, he's not even close to being in the same league. Matt absolutely has no vision or any CEO experience close to Mel and Elon to drive this company to a success level that the latter 2 have done. It's like comparing a Ford Pinto to a Lambo. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 4, 2017 9:00:34 GMT -5
Looks bad. Agreed. Too bad the insulin works so well. If it worked that well you would see a significant number of refills. I do not buy that people do not refill due to price. Who would fill a script if they knew they couldn't afford to refill it? The reality is, not many are having success with Afrezza that we thought we'd see. I think it works that well but it is a niche because not all PWD get dialed in as easy as others. Some might get dialed in fairly easy while others may have a tougher time. I think the early adopters that you read about are ones who are ahead of the curve on their disease. MNKD's impact on helping PWD get dialed in correctly has failed because 1) They are on a shoe string budget 2) Even they needed to figure some things out. There are more people out there discussing the cons and MNKD does not have the staff to tell a different story. They wanted to go at it alone because they thought they were dupped, and now they are seeing the catch 22 of going at it alone. If you are trying to re invent the wheel and change the ideology you cannot do it with contract sales reps and now a smaller sales force. |
|
